Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16069679 | 0.86 | APP (0.81) | APPCYP1A2CA12CA9TLR7 | |
| SCHEMBL16196000 | 0.85 | APP (0.80) | APPCYP1A2CA12CA9TLR7 | |
| SCHEMBL31492097 | 0.84 | APP (0.78) | APPCYP1A2CA12MAOAMAOB | |
| SCHEMBL505449 | 0.84 | APP (0.78) | APPCYP1A2CA12MAOAMAOB | |
| SCHEMBL10167874 | 0.83 | APP (1.00) | APPCYP1A2 | |
| SCHEMBL10167880 | 0.82 | APP (1.00) | APPCYP1A2TLR7 | |
| SCHEMBL10167882 | 0.81 | APP (1.00) | APPCYP1A2TLR7 | |
| Ethoxyresorufin SCHEMBL31079400 | 0.81 | APP (1.00) | APPCYP1A2CA12CA9 | |
| Ethoxyresorufin SCHEMBL104497 | 0.81 | APP (1.00) | APPCYP1A2CA12CA9 | |
| SCHEMBL30278760 | 0.80 | APP (0.72) | APPCYP1A2CA12MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205461-A1 | Rapidly Released Bioorthogonal Caging Groups | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205461-A1 | Rapidly Released Bioorthogonal Caging Groups | CBR3, CBR1, CNOT9 | APP 4830/4885CYP1A2 2884/4885PDE3B 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.